Figure 3.

Failure of lopinavir/ritonavir (LPV/r) monotherapy was defined as confirmed virologic failure (failure to suppress plasma human immunodeficiency virus type 1 [HIV-1] RNA level to <400 copies/mL by week 24, or confirmed rebound of plasma HIV-1 RNA level to >400 copies/mL after confirmed suppression to <400 copies/mL) or discontinuation of LPV/r monotherapy. The solid line represents the study's primary endpoint, defined as virologic failure or LPV/r intensification. The dotted line represents a clinical endpoint, defined as the first occurrence of disease progression (World Health Organization stage 4 event) or death. Shaded areas denote 95% confidence intervals.